Background and Aims

MDC is an FDA-approved digital solution comprising a smartphone app for people with T2D and web portal for healthcare professionals (HCPs). The HCP defines an individualised long-acting basal insulin (BI) titration plan that is used by MDC to give dose recommendations to the user based on their fasting blood glucose (FBG) readings and hypoglycaemic event data.

Methods

The analysis included people with T2D in India who were registered for MDC by their HCP from 01/09/2018 to 31/03/2019 and received insulin glargine 100 U/mL or 300 U/mL. Users logged FBG and BI doses administered directly in MDC. Users reaching titration target were defined as those who logged three consecutive FBG measurements within their prescribed target range. Hypoglycaemic events were defined as below HCP-defined hypoglycaemia cut-off per the dose plan.

Results

Among 684 people who were registered with MDC and recorded ≥2 FBG readings over a 2-week period, 295 reached their FBG targets. From starting titration to reaching goal, mean FBG decreased from 168.5 to 107.7 mg/dL (−36%), and mean BI dose increased from 17.1 to 19.8 U (+16%). Mean time to reach goal was 18.1 days, with an average of 1 hypoglycaemic event per user. Users who up-titrated had higher mean starting FBG and greater FBG decrease compared with those with stable or decreased dose (Table).

Conclusions

Many MDC users were able to successfully titrate their BI and achieve target FBG, showing the potential for simple digital titration solutions to assist diabetes management in appropriate patient profiles in a resource-limited setting.

Sponsored by Sanofi.